Variations of therapeutic KDs might provide benefits for breast cancer by decreasing tumor necrosis factor alpha (TNF-α) and insulin while increasing interleukin 10 (IL-10) (116) and may be a promising adjuvant therapy for various cancers (117, –, 121). The gene discussed is TNF; the disease is breast carcinoma.